PrecisionLife and Nanopharmaceutics Join Forces to Advance Precision Medicine for CNS Disorders

In a groundbreaking move towards revolutionizing the treatment of central nervous system (CNS) disorders, PrecisionLife, a leading techbio company specializing in precision medicine, and Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, have announced a strategic collaboration. This partnership aims to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of CNS assets through the power of precision medicine.

Harnessing the Power of Combinatorial Analytics

At the core of this collaboration lies PrecisionLife’s proprietary combinatorial analytics platform, a cutting-edge technology that analyzes patient genomic profiles. This platform will be leveraged to identify target-specific genetic biomarkers for each of Nanopharmaceutics’ CNS drug development programs. These biomarkers will be based on combinations of single nucleotide polymorphisms (SNPs) specifically associated with the mechanisms of action and development indications of Nanopharmaceutics’ drugs.

Optimizing Clinical Development through Patient Stratification

Under the collaboration, PrecisionLife will lend its support to Nanopharmaceutics in the clinical development of their CNS programs. This support will involve identifying patient stratification biomarkers that link the mechanisms of action of the development compounds to patient subgroups most likely to exhibit positive outcomes in clinical trials. This approach optimizes patient selection, increasing the probability of success in these trials.

Exclusive Rights and Additional Applications

As part of the collaboration, Nanopharmaceutics will have the option to negotiate an exclusive right to the patient stratification biomarkers discovered through the PrecisionLife platform. This strategic advantage provides Nanopharmaceutics with the opportunity to further enhance their precision and effectiveness in clinical trials for CNS disorders.

The precision medicine approach employed by PrecisionLife and Nanopharmaceutics holds the potential to significantly improve the success rates of clinical trials, even for the most complex chronic diseases. Moreover, beyond the scope of this collaboration, the biomarkers discovered by PrecisionLife may serve as invaluable complementary diagnostic tools. This could expedite the approval process for new therapeutic products, ensuring the swift delivery of the latest medicines to patients with unmet medical needs.

Enthusiasm from Key Players

Commenting on the collaboration, Dr. James Talton, President and CEO of Nanopharmaceutics, expressed his excitement about partnering with PrecisionLife. He emphasized their shared commitment to creating targeted therapeutic products and highlighted how this collaboration would enhance the precision and effectiveness of clinical trials for CNS disorders, which have historically posed significant challenges due to their complexity.

Echoing the sentiment, Dr. Steve Gardner, CEO and Co-founder of PrecisionLife, affirmed their company’s proficiency in identifying the combinations of genetic and non-genetic features responsible for an individual’s disease subtypes. This capability allows for the design of smaller, faster-to-readout clinical trials, specifically tailored to each drug’s mechanism of action. Dr. Gardner further expressed delight in supporting Nanopharmaceutics’ clinical development efforts with precision biomarkers, which will accelerate and de-risk the development of targeted therapeutic products for patients in urgent need.

A Promising Milestone for Precision Medicine

The collaboration between PrecisionLife and Nanopharmaceutics represents a significant milestone in the pursuit of precision medicine for complex chronic diseases. By utilizing mechanistic patient stratification biomarkers to inform clinical trial design, these two pioneering companies are set to transform the lives of patients living with CNS disorders. This collaboration exemplifies the power of precision medicine and brings hope for more effective treatments in the future.

About PrecisionLife

PrecisionLife, a pioneering techbio company, is transforming the landscape of predicting, preventing, and treating chronic diseases. Their mission revolves around discovering improved and personalized treatment options for patients who have unmet medical needs. Their focus extends beyond oncology and rare diseases to encompass complex common diseases that account for a significant portion of healthcare spending, amounting to over 80%.

The company’s approach is driven by innovation, employing a combinatorial methodology that delves deep into disease biology. This unique approach enables them to achieve mechanistic patient stratification, even in conditions characterized by high heterogeneity.

PrecisionLife boasts an extensive repository of information and intellectual property that spans across 45 indications. This vast knowledge base has allowed them to develop one of the most comprehensive pipelines for precision targeted therapies. Armed with this wealth of information, they have the ability to inform and de-risk every stage of biopharma innovation, from the initial concept to clinical implementation.

For more information on PrecisionLife’s groundbreaking work, visit their website at precisionlife.com. Stay connected with them on LinkedIn by following @PrecisionLifeAI and on Twitter at @PrecisionLifeAI.

About Nanopharmaceutics, Inc.

Nanopharmaceutics, Inc., operating as a clinical-stage specialty pharmaceutical company, is dedicated to the development of a diverse range of products. Their portfolio includes oral, topical, and injectable medications targeting cancer, central nervous system (CNS) disorders, and infectious diseases. Through their extensive knowledge and proficiency in nanoparticle and fine-particle formulations, Nanopharmaceutics aims to enhance the delivery of challenging Biopharmaceutics Classification System (BCS) category II and IV drugs. The company places a strong emphasis on formulation development to optimize drug absorption and stability, opening up new possibilities for improved therapeutic outcomes.

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES